Eli Lilly Expands Zepbound Doses, Adds New Safeguards

Eli Lilly announced that the highest approved doses of its weight-loss drug Zepbound (12.5 mg and 15 mg) will soon be available in single-dose vials through LillyDirect Self Pay Pharmacy Solutions, with prescriptions starting on July 7 and shipments beginning in early August. All strengths, from 2.5 mg to 15 mg, will be offered at $499 per month or less for self-paying adults with obesity or overweight with weight-related medical issues, regardless of insurance status. Zepbound is also available in single-dose pens. Clinical trials have shown that patients using the 15 mg dose lost an average of 21% of their body weight. The company highlights the urgency of treating obesity as a chronic disease and aims to improve access with competitive pricing. Zepbound is not approved for children and should not be used with other tirzepatide-containing products or GLP-1 receptor agonists.